Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by lonc17on Apr 11, 2024 11:20am

123 Views

Post# 35983373

FDA Meeting

Breaking News!

ONC has requested a meeting with the FDA!!

Shareholders rejoice!

Matt continues to work very hard to give the impression that ONC is a legitmate company rapidly progressing to TWO phase 3 trials ... oh, sorry, I meant TWO registration enabling trials.

I'm so very proud of the accomplishments ONC has achieved in its short 25 year history.

Next anticipated milestone: Matt's monthy $150,000 paycheck.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec